Newfound PARP-1 role becomes a promising target in prostate cancer

The enzyme PARP-1 is already well-known for its role in DNA damage repair, but scientists recently discovered that it also contributes to the growth and progression of androgen receptor-positive prostate cancer cells. This means that PARP inhibitors might be able to suppress androgen receptor activity, which fuels prostate tumor growth.

PARP-1, more formally known as poly(ADP-ribose) polymerase-1, is already a target of cancer therapy because of its involvement in DNA damage repair for cancer cells. In the latest research, a team led by Karen E. Knudsen, PhD, of Thomas Jefferson University in Philadelphia, Pennsylvania, learned through various in vitro and in vivo model systems that PARP-1 activity is required for androgen receptor function and is increased in castration-resistant prostate cancer. In this advanced stage of prostate cancer, chemotherapy and other treatments have little to no effect. Nearly 40% of men with prostate cancer progress to castration-resistant disease.

The investigators also found that inhibiting PARP-1 suppressed proliferation of cultured, primary human tumor specimens in a state-of-the art system.

“Collectively, these studies identify novel functions of PARP-1 in promoting disease progression, and ultimately suggest that the dual functions of PARP-1 can be targeted in human prostate cancer to suppress tumor growth and progression to castration-resistance,” wrote the authors in Cancer Discovery.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs